ArticleESMO gastrointestinal oncology2026

Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors.

G R de Almeida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.